Maxillofacial Plastic and Reconstructive Surgery

  • Volume 39
  • /
  • Pages.1.1-1.7
  • /
  • 2017
  • /
  • 2288-8101(pISSN)
  • /
  • 2288-8586(eISSN)
Korean Association of Maxillofacial Plastic and Reconstructive Surgeons (대한악안면성형재건외과학회)
권호 표지
DOI QR코드

DOI QR Code

Medication-related osteonecrosis of the jaw: a preliminary retrospective study of 130 patients with multiple myeloma

  • Choi, Woo-Sung (Department of Oral and Maxillofacial Surgery, College of Medicine, Soonchunhyang University Cheonan Hospital) ;
  • Lee, Jae-Il (Department of Oral and Maxillofacial Surgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
  • Yoon, Hyun-Joong (Department of Oral and Maxillofacial Surgery, College of Medicine, Bucheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
  • Min, Chang-Ki (Department of Hematology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
  • Lee, Sang-Hwa (Department of Dentistry, St. Paul's Hospital, College of Medicine The Catholic University of Korea)
  • Received : 2016.11.13
  • Accepted : 2016.12.13
  • Published : 2017.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Multiple myeloma (MM) is characterized by a neoplastic proliferation of plasma cells primarily in the bone marrow. Bisphosphonates (BP) are used as supportive therapy in the management of MM. This study aimed to analyze the incidence, risk factors, and clinical outcomes of medication-related necrosis of the jaw (MRONJ) in MM patients. Methods: One hundred thirty MM patients who had previous dental evaluations were retrospectively reviewed. Based on several findings, we applied the staging and treatment strategies on MRONJ. We analyzed gender, age, type of BP, incidence, and local etiological factors and assessed the relationship between these factors and the clinical findings at the first oral examination. Results: MRONJ was found in nine male patients (6.9%). The mean patient age was 62.2 years. The median BP administration time was 19 months. Seven patients were treated with a combination of IV zoledronate and pamidronate, and two patients received single-agent therapy. The lesions were predominantly located in the mandible (n = 8), and the most common predisposing dental factor was a history of prior extraction (n = 6). Half of the MRONJ were related to diseases found on the initial dental screen. Patients with MRONJ were treated with infection control and antibiotic therapy. When comparing between the MRONJ stage and each factor (sign, location, etiologic factor, BP type, treatment, and outcome), there were no significant differences between stages, except for between the stage and sign (with or without purulence). Conclusions: For prevention of MRONJ, we recommend routine dental examinations and treatment prior to starting BP therapy.

Keywords

References

  1. Tricot G (2000) Multiple myeloma and other plasma cell disorders. Hematology: basic principles and practice, 3rd edn. Churchill Livingstone, Philadelphia, pp 1398-416
  2. Won YJ, Sung J, Jung KW, Kong HJ, Park S, Shin HR, Park EC, Ahn YO, Hwang IK, Lee DH (2009) Nationwide cancer incidence in Korea, 2003-2005. Cancer Res Treat 41:122-31 https://doi.org/10.4143/crt.2009.41.3.122
  3. Mhaskar R, Redzepovic J, Wheatley K, Clark OA, Miladinovic B, Glasmacher A, Kumar A, Djulbegovic B (2012) Bisphosphonates in multiple myeloma: a network meta-analysis. Cochrane Database Rev 16:CD003188.
  4. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL (2004) Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62:527-34 https://doi.org/10.1016/j.joms.2004.02.004
  5. Badros A, Weikel D, Salama A, Goloubeva O, Schneider A, Rapoport A, Fenton R, Gahres N, Sausville E, Ord R, Meiller T (2006) Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol 24:945-52 https://doi.org/10.1200/JCO.2005.04.2465
  6. Boonyapakorn T, Schirmer I, Reichart PA, Sturm I, Massenkeil G (2008) Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies. Oral Oncol 44:857-69 https://doi.org/10.1016/j.oraloncology.2007.11.012
  7. Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, Koutsoukou V, Gika D, Anagnostopoulos A, Papadimitriou C, Terpos E, Dimopoulos MA (2005) Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 23:8580-7 https://doi.org/10.1200/JCO.2005.02.8670
  8. Marx RE (2003) Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61:1115-7 https://doi.org/10.1016/S0278-2391(03)00720-1
  9. Kos M, Kuebler JF, Luczak K, Engelke W (2010) Bisphosphonate-related osteonecrosis of the jaws: a review of 34 cases and evaluation of risk. J Craniomaxillofac Surg 38:255-9 https://doi.org/10.1016/j.jcms.2009.06.005
  10. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B (2009) American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws-2009 update. J Oral Maxillofac Surg Suppl 67:2-12 https://doi.org/10.1016/S0278-2391(09)01877-1
  11. Bagan J, Scully C, Sabater V, Jimenez Y (2009) Osteonecrosis of the jaws in patients treated with intravenous bisphosphonates (BRONJ): a concise update. Oral Oncol 45:551-4 https://doi.org/10.1016/j.oraloncology.2009.01.002
  12. Berenson JR, Yellin O, Crowley J, Makary A, Gravenor DS, Yang HH, Upadhyaya GH, Flinn IW, Staszewski H, Tiffany NM, Sanani S, Farber CM, Morganstein N, Bolejack V, Nassir Y, Hilger JD, Sefaradi A, Shamouelian A, Swift RA (2011) Prognostic factors and jaw and renal complications among multiple myeloma patients treated with zoledronic acid. Am J Hematol 86:25-30 https://doi.org/10.1002/ajh.21912
  13. Corso A, Varettoni M, Zappasodi P, Klersy C, Mangiacavalli S, Pica G, Lazzarino M (2007) A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma. Leukemia 21:1545-8 https://doi.org/10.1038/sj.leu.2404682
  14. Zervas K, Verrou E, Teleioudis Z, Vahtsevanos K, Banti A, Mihou D, Krikelis D, Terpos E (2006) Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients. Br J Haematol 134:620-3 https://doi.org/10.1111/j.1365-2141.2006.06230.x
  15. Dimopoulos MA, Kastritis E, Anagnostopoulos A, Melakopoulos I, Gika D, Moulopoulos LA, Bamia C, Terpos E, Tsionos K, Bamias A (2006) Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. Haematologica 91:968-71
  16. Ruggiero SL, Drew SJ (2007) Osteonecrosis of the jaws and bisphosphonate therapy. J Dent Res 86:1013-21 https://doi.org/10.1177/154405910708601101
  17. Ikebe T (2013) Pathophysiology of BRONJ: drug-related osteoclastic disease of the jaw. Oral Sci Int 10:1-8 https://doi.org/10.1016/S1348-8643(12)00045-6
  18. Wen D, Qing L, Harrison G, Golub E, Akintoye SO (2011) Anatomic site variability in rat skeletal uptake and desorption of fluorescently labeled bisphosphonate. Oral Dis 17:427-32 https://doi.org/10.1111/j.1601-0825.2010.01772.x
  19. Kozloff KM, Volakis LI, Marini JC, Caird MS (2010) Near-infrared fluorescent probe traces bisphosphonate delivery and retention in vivo. J Bone Miner Res 25:1748-58 https://doi.org/10.1002/jbmr.66
  20. Marx RE, Sawatari Y, Fortin M, Broumand V (2005) Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 63:1567-75 https://doi.org/10.1016/j.joms.2005.07.010
  21. Marx RE (1983) Osteoradionecrosis: a new concept of its pathophysiology. J Oral Maxillofac Surg 41:283-8 https://doi.org/10.1016/0278-2391(83)90294-X
  22. Wood J, Bonjean K, Ruetz S, Bellahcene A, Devy L, Foidart JM, Castronovo V, Green JR (2002) Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 302:1055-61 https://doi.org/10.1124/jpet.102.035295
  23. Wutzl A, Pohl S, Sulzbacher I, Seemann R, Lauer G, Ewers R, Drach J, Klug C (2012) Factors influencing surgical treatment of bisphosphonate-related osteonecrosis of the jaws. Head Neck 34:194-200 https://doi.org/10.1002/hed.21708
  24. Ruggiero S, Gralow J, Marx RE, Hoff AO, Schubert MM, Huryn JM, Toth B, Damato K, Valero V (2006) Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer. J Oncol Pract 2:7-14 https://doi.org/10.1200/jop.2006.2.1.7
  25. Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, Gagel RF, Gilsanz V, Guise T, Koka S, McCauley LK, McGowan J, McKee MD, Mohla S, Pendrys DG, Raisz LG, Ruggiero SL, Shafer DM, Shum L, Silverman SL, Van Poznak CH, Watts N, Woo SB, Shane E (2007) Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 22:1479-91 https://doi.org/10.1359/jbmr.0707onj
  26. Hoff AO, Toth BB, Altundag K, Johnson MM, Warneke CL, Hu M, Nooka A, Sayegh G, Guarneri V, Desrouleaux K, Cui J, Adamus A, Gagel RF, Hortobagyi GN (2008) Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 23:826-36 https://doi.org/10.1359/jbmr.080205
  27. Van den Wyngaert T, Claeys T, Huizing MT, Vermorken JB, Fossion E (2009) Initial experience with conservative treatment in cancer patients with osteonecrosis of the jaw (ONJ) and predictors of outcome. Ann Oncol 20:331-6

Cited by

  1. Erratum to: Usefulness and capability of three-dimensional, full high-definition movies for surgical education vol.39, pp.None, 2017, https://doi.org/10.1186/s40902-017-0124-2
  2. Acid-etching technique of non-decalcified bone samples for visualizing osteocyte-lacuno-canalicular network using scanning electron microscope vol.42, pp.1, 2017, https://doi.org/10.1080/01913123.2017.1384418
  3. Prognostic factors for outcome of surgical treatment in medication-related osteonecrosis of the jaw vol.44, pp.4, 2017, https://doi.org/10.5125/jkaoms.2018.44.4.174
  4. Effects of an oral bisphosphonate and three intravenous bisphosphonates on several cell types in vitro vol.22, pp.7, 2017, https://doi.org/10.1007/s00784-018-2349-6
  5. Technique of the Buccal Fat Pad Flap as an Alternative for the Surgical Defect of Pleomorphic Adenoma : vol.30, pp.3, 2017, https://doi.org/10.1097/scs.0000000000004890
  6. Fracture risk following intermission of osteoporosis therapy vol.30, pp.9, 2017, https://doi.org/10.1007/s00198-019-05002-w
  7. Different Presentation and Outcomes in the Surgical Treatment of Advanced MRONJ in Oncological and Nononcological Patients Taking or Not Corticosteroid Therapy vol.2021, pp.None, 2017, https://doi.org/10.1155/2021/7855497
  8. The treatment gap: The missed opportunities for osteoporosis therapy vol.144, pp.None, 2017, https://doi.org/10.1016/j.bone.2020.115833
  9. Review of Myeloma Therapies and Their Potential for Oral and Maxillofacial Side Effects vol.13, pp.17, 2017, https://doi.org/10.3390/cancers13174479
  10. Review and Update of the Risk Factors and Prevention of Antiresorptive-Related Osteonecrosis of the Jaw vol.36, pp.5, 2021, https://doi.org/10.3803/enm.2021.1170
  11. Medication Related Osteonecrosis of the Jaw: 2021 Position Statement of the Korean Society for Bone and Mineral Research and the Korean Association of Oral and Maxillofacial Surgeons vol.28, pp.4, 2017, https://doi.org/10.11005/jbm.2021.28.4.279